Intestinal Failure-Associated Liver Disease in Neonates.
The article reviews the epidemiology and factors that contribute to intestinal failure-associated liver disease in neonates, in addition to management strategies.
The article reviews the epidemiology and factors that contribute to intestinal failure-associated liver disease in neonates, in addition to management strategies.
Trial of a clinically approved parenteral fish‐oil emulsion providing an eicosapentaenoic acid/docosahexaenoic acid combination for the management of the hyperinflammatory state or “cytokine storm” found in some critically ill patients infected with COVID‐19.
Purpose was to investigate changes in plasma miR-122, correlate miR-122 with serum liver function tests, and investigate changes in whole blood transcripts including miR-122 targets in children with intestinal failure-associated liver disease who received pure intravenous fish oil as a treatment for cholestasis.